Pharma Latch is developing a series of healthcare professional and self-administered intradermal injection devices based on an innovative angled needle platform technology. We are funded through venture capital, and more recently by West Pharmaceutical Services.
The Pharma Latch platform simplifies and de-risks intradermal delivery by providing consistent and complete dose delivery of any liquid formulation (up to: 3 mL, 60 cP). These features allow intradermal to be considered a realistic option to the pharmaceutical industry for the first time as well as enabling new applications beyond what was previously thought possible (higher volume formulations, eg., biologics).
Our first product, the Pharma Latch Hollow (PLH), is currently under development as a sterile-packed, single-use medical device (Class II, FDA 510(k) pathway) and is in late-stage manufacturing in the USA. The PLH is ready for use in pre-clinical studies now (in small or large animals) with clinical evaluation planned for 2025. A series of self-injector devices, composed of the same core platform technology are also under development.